A Randomized Phase II Study of Sotorasib versus Continued Consolidation Durvalumab in Patients with KRAS G12C Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) with Persistent ctDNA Defined Minimal Residual Disease

Disease Sites:

Lung

Staging:

Phase II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Durvalumab, Sotorasib

Principal Investigator(s):

Whitaker, Ryan

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

04-16-2025

Trial Type:

Treatment

Protocol ID:

VICC-ITTHO23274

National Clinical Trial ID:

NCT06333678

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available